Better Classification of Respiratory Amyloidosis
B-AR
Towards a Better Classification of Respiratory Amyloidosis. Contribution of Proteomic Analysis Based on Tandem Mass Spectrometry
1 other identifier
observational
70
0 countries
N/A
Brief Summary
The B-AR project is based on a retrospective analysis of amyloidosis typing and the identification of their amylogenic protein.This work should be able to unite many clinicians, including pulmonologists and pathologists around a rare disease that still suffers from insufficient data.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started May 2023
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 27, 2023
CompletedStudy Start
First participant enrolled
May 15, 2023
CompletedFirst Posted
Study publicly available on registry
May 17, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 15, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
May 15, 2026
CompletedMay 17, 2023
March 1, 2023
2 years
March 27, 2023
May 15, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of cases with identification of the amylogenic protein in respiratory amyloidosis.
Identification of amylogenic protein by Proteomic Analysis Based on Tandem Mass Spectrometry on histological sample of the tracheobronchial or pulmonary tree.
1 day (at inclusion)
Secondary Outcomes (1)
Distribution and severity of amyloidosis
1 day (at inclusion)
Eligibility Criteria
patients with respiratory amyloidosis
You may qualify if:
- Adult patient \> to 18 years with amyloidosis on a histological sample of the tracheobronchial or pulmonary tree.
You may not qualify if:
- Subject receiving state medical aid
- Subject deprived of freedom, or under a legal protective measure (example: patients under guardianship or curators)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Biospecimen
fixed tissue (Lung biopsy, Bronchial biopsy; trans-thoracic lung biopsy, trans-bronchial lung biopsy).
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Yurdagül UZUNHAN, Pr,MD, PhD
APHP Hôpital Avicenne
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 27, 2023
First Posted
May 17, 2023
Study Start
May 15, 2023
Primary Completion
May 15, 2025
Study Completion
May 15, 2026
Last Updated
May 17, 2023
Record last verified: 2023-03